CN100355416C - Cassia twig and poria cocos disperse tablet and its producing method - Google Patents
Cassia twig and poria cocos disperse tablet and its producing method Download PDFInfo
- Publication number
- CN100355416C CN100355416C CNB2004100514849A CN200410051484A CN100355416C CN 100355416 C CN100355416 C CN 100355416C CN B2004100514849 A CNB2004100514849 A CN B2004100514849A CN 200410051484 A CN200410051484 A CN 200410051484A CN 100355416 C CN100355416 C CN 100355416C
- Authority
- CN
- China
- Prior art keywords
- gram
- cassia twig
- grams
- concentrated
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000008599 Poria cocos Nutrition 0.000 title claims abstract description 36
- 244000037364 Cinnamomum aromaticum Species 0.000 title claims abstract description 35
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims description 11
- 244000197580 Poria cocos Species 0.000 title description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 36
- 235000001188 Peltandra virginica Nutrition 0.000 claims abstract description 34
- 239000007788 liquid Substances 0.000 claims abstract description 34
- 239000000843 powder Substances 0.000 claims abstract description 18
- 238000005469 granulation Methods 0.000 claims abstract description 5
- 230000003179 granulation Effects 0.000 claims abstract description 5
- 244000248825 Peltandra virginica Species 0.000 claims abstract 11
- 239000007919 dispersible tablet Substances 0.000 claims description 38
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 30
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 210000000582 semen Anatomy 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 11
- 229910052708 sodium Inorganic materials 0.000 claims description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 239000012567 medical material Substances 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 239000012065 filter cake Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 235000014666 liquid concentrate Nutrition 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 32
- 239000008280 blood Substances 0.000 abstract description 32
- 239000003814 drug Substances 0.000 abstract description 20
- 230000017531 blood circulation Effects 0.000 abstract description 12
- 238000002360 preparation method Methods 0.000 abstract description 7
- 210000001015 abdomen Anatomy 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 5
- 201000000736 Amenorrhea Diseases 0.000 abstract description 3
- 206010001928 Amenorrhoea Diseases 0.000 abstract description 3
- 244000144730 Amygdalus persica Species 0.000 abstract description 3
- 208000005171 Dysmenorrhea Diseases 0.000 abstract description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract description 3
- 240000005001 Paeonia suffruticosa Species 0.000 abstract description 3
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract description 3
- 231100000540 amenorrhea Toxicity 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 238000004090 dissolution Methods 0.000 abstract description 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 3
- 239000001116 FEMA 4028 Substances 0.000 abstract 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 3
- 229960004853 betadex Drugs 0.000 abstract 3
- 241000736199 Paeonia Species 0.000 abstract 2
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 abstract 2
- 208000021129 Postpartum disease Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 16
- 230000001737 promoting effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 229960003387 progesterone Drugs 0.000 description 8
- 239000000186 progesterone Substances 0.000 description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 7
- 229960005309 estradiol Drugs 0.000 description 7
- 229930182833 estradiol Natural products 0.000 description 7
- 239000006187 pill Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000004089 microcirculation Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 206010000077 Abdominal mass Diseases 0.000 description 4
- -1 B-elemene Chemical compound 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102000003946 Prolactin Human genes 0.000 description 3
- 108010057464 Prolactin Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000002338 glycosides Chemical group 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229940097325 prolactin Drugs 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- 206010057687 Bloody discharge Diseases 0.000 description 2
- 241000205571 Caulophyllum Species 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid group Chemical group C(C=CC1=CC=CC=C1)(=O)O WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- OOCCDEMITAIZTP-QPJJXVBHSA-N (E)-cinnamyl alcohol Chemical compound OC\C=C\C1=CC=CC=C1 OOCCDEMITAIZTP-QPJJXVBHSA-N 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 description 1
- ATWHGWYKSFRYBN-UHFFFAOYSA-N Amygdaloside Natural products O1C(=O)C2(C)CCCC(C3CC4)(C)C2C1OCC3(C1)CC4C1(O)COC1OC(CO)C(O)C(O)C1O ATWHGWYKSFRYBN-UHFFFAOYSA-N 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 206010035588 Pleural adhesion Diseases 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- 241000220299 Prunus Species 0.000 description 1
- 240000002381 Prunus davidiana Species 0.000 description 1
- 235000015533 Prunus davidiana Nutrition 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- OOCCDEMITAIZTP-UHFFFAOYSA-N allylic benzylic alcohol Natural products OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 125000002871 cinnamic aldehydes group Chemical group 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000009748 deglutition Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a cassia twig and tuckahoe dispersive tablet which is mainly prepared from cassia twig, tuckahoe, tree peony bark, red peony root, peach kernel, beta-cyclodextrin and relevant auxiliary materials. The present invention is formed by the following preparation steps: the cassia twig and the tree peony bark are mixed and are extracted for forming medicine liquid and medicine dregs; the medicine liquid is concentrated, and the beta-cyclodextrin is added to concentrated liquid; the concentrated liquid and the beta-cyclodextrin are dried and crushed for forming fine powder; the tuckahoe, the red peony root, the peach kernel and the medicine dregs are decocted in water together; medicine dregs are separated for forming water decoction liquid; the water decoction liquid is concentrated, dried and crushed into fine powder; the fine power formed in the previous two steps are mixed, and auxiliary materials are added to the mixed fine powder; the dispersive tablet is formed by pressing after granulation. The cassia twig and tuckahoe dispersive tablet of the present invention has the functions of activating blood circulation, removing blood stasis and eliminating lumps in the abdomen. The present invention is used for treating lumps in the abdomen of a woman, or blood stasis and amenorrhea, dysmenorrhea and postpartum diseases. The present invention has the characteristics of safety, effectiveness, small dosage, strong therapeutic effect, rapid dissolution, convenient administration, high medicinal bioavailability, etc. Moreover, the present invention has simple preparation technology and strong stability. After the dispersive tablet is dispersed in water, the dispersive tablet can be taken orally or can be swallowed.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of gynaecopathia, particularly relate to a kind of medicine by the preparation of medical materials such as Ramulus Cinnamomi, Poria.
Background technology
Along with social development, also great changes will take place for physical environment and sanitary condition, very big variation has also taken place in the natural environment that the mankind depend on for existence, cause paathogenic factor also to be among the continuous development and change, some deleterious life style and bad diet style all can cause the generation of human diseases in addition.Nowadays social, the gynaecopathia sickness rate is high always.Because the specificity of female pathology structure causes infection probability and sickness rate all to be far longer than other section's disease, as hysteromyoma, endometriosis, pelvic inflammatory disease, dysmenorrhea etc.Research and development prevention and the new drug for the treatment of this type of disease will have incomparable huge market prospect, also will produce remarkable economic efficiency and social benefit.
Chinese medicine and pharmacy is the treasure-house of a greatness, and the traditional Chinese medical science has original opinion to gynaecopathia, is that doctor trained in Western medicine is incomparable.It is dialectical and control the theory of effecting a permanent cure, extensive knowledge and profound scholarship, lose the medicine prescription, even better, tradition name side Ramulus Cinnamomi Poria pill comes from the Han dynasty and cures holy Zhang Zhongjing " Medical Treasures of the Golden Chamber married woman gestation abnormal pulse card is also controlled ", do not wane with containing for a long time, curative effect is peculiar, now collect " Ramulus Cinnamomi Poria pill that Chinese pharmacopoeia version in 2000 is the 549th page, it has invigorating blood circulation blood stasis dispelling, the slow leprosy piece that disappears, there is the scar piece treatment married woman place, or the blood stasis amenorrhea, menalgia, lochia.The applicating history in more than 1,000 year shows, we's determined curative effect is reliable, and safety is good, but along with modern social development, the human civilization progress, the cassia twig tuckahoe harm has been difficult to the paces of keeping pace with the times, and this side is usefulness with the ball, all based on medicinal powder, Mel is auxilliary, cause dose big, drug effect is slow, and indigestibility, bioavailability is low, and exist disintegration rate slow, and the influence certain to being absorbed with of medicine, the dosage form volume is big, and once need to take many, need to use mixing in water for oral taking, take inconvenience, old to giving especially, children and have the patient of function of deglutition obstacle that certain difficulty is arranged.
Summary of the invention
The present invention is intended to solve in the prior art that the Ramulus Cinnamomi Poria pill dose is big, and drug effect is slow, and indigestibility, and bioavailability is low, take shortcomings such as inconvenience and a kind of cassia twig tuckahoe dispersible tablet and preparation method thereof is provided.
Technical scheme of the present invention is: a kind of cassia twig tuckahoe dispersible tablet is provided, and the prescription that is pressed into 1000 comprises:
Ramulus Cinnamomi 100-500 gram Poria 100-500 gram Cortex Moutan 100-500 gram
Radix Paeoniae Rubra 100-500 gram Semen Persicae 100-500 gram beta-schardinger dextrin-10-50 gram.
Contain crospolyvinylpyrrolidone 20-150 gram in the described prescription, micropowder silica gel 1-10 gram, magnesium stearate 0.5-10 gram, microcrystalline Cellulose 50-300 gram, carboxymethyl starch-sodium 50-300 gram.
With medical material and the adjuvant of suppressing 1000 dispersible tablets be:
Ramulus Cinnamomi 360 gram Poria 360 gram Cortex Moutans 360 grams
Radix Paeoniae Rubra 360 gram Semen Persicaes 360 gram beta-schardinger dextrin-s 36 grams
Crospolyvinylpyrrolidone 75 gram micropowder silica gels 5 grams
Magnesium stearate 2.5 gram microcrystalline Cellulose 175 grams
Carboxymethyl starch-sodium 90 grams.
The present invention also provides a kind of cassia twig tuckahoe dispersible tablet manufacture method, carries out as follows:
(1) takes by weighing each 100-500 gram of Ramulus Cinnamomi, Cortex Moutan and mix, add again, each 1～2 hour, make medicinal liquid and medicinal residues after the filtration with respect to 90% alcohol reflux of Ramulus Cinnamomi, 8 times of amounts of Cortex Moutan gross weight at least 2 times;
(2) the gained medicinal liquid is concentrated, leave standstill the supernatant of getting concentrated solution after 24 hours, and in this supernatant, add 10～50 the gram beta-schardinger dextrin-s, and under 50～60 ℃, be incubated 20～40 minutes, add 50～60 ℃ water again, stirred 20～40 minutes, place 10 ℃ of following cold preservations of temperature 60～80 hours with respect to 2 times of weight of medicinal liquid, with the filter cake cold drying, and pulverize and to make fine powder after the filtration;
(3) medicinal residues of each 100-500 gram of Poria, Radix Paeoniae Rubra, Semen Persicae with step (1) in are decocted separation medicinal residues and make decocting liquid in water;
(4) the decocting liquid in the step (3) is concentrated, dry, pulverizing forms fine powder;
(5) fine powder of step (2) and step (4) mixes and adds adjuvant, through granulation, and is pressed into dispersible tablet.
With medical material and the adjuvant of suppressing 1000 dispersible tablets be:
Ramulus Cinnamomi 360 gram Poria 360 gram Cortex Moutans 360 grams
Radix Paeoniae Rubra 360 gram Semen Persicaes 360 gram beta-schardinger dextrin-s 36 grams
Crospolyvinylpyrrolidone 75 gram micropowder silica gels 5 grams
Magnesium stearate 2.5 gram microcrystalline Cellulose 175 grams
Carboxymethyl starch-sodium 90 grams.
It is 1.00 gram/cubic centimetres when medicinal liquid is concentrated into relative density and is 50～60 ℃ that described step (2) herb liquid concentrates.
Decocting liquid in the described step (3) is that Semen Persicae is smashed to pieces, decoct with water at least 2 times with the medicinal residues mixture after Poria, Radix Paeoniae Rubra and Ramulus Cinnamomi, the Cortex Moutan alcohol extraction, add for the first time water with respect to 10 times of amounts of described mixture weight, add for the second time 8 times of water gagings, the each decoction 1～2 hour makes decocting liquid after the filtration.
In the described step (4) decocting liquid being concentrated is the clear paste of 1.12～1.15 gram/cubic centimetres when concentrated solution is concentrated into relative density and is 50～60 ℃.
The invention has the beneficial effects as follows: the cassia twig tuckahoe dispersible tablet is through extraction separation and add adjuvants such as beta-schardinger dextrin-and make dispersible tablet by Chinese medicine of the five flavours such as Ramulus Cinnamomi, Poria, Cortex Moutan, Radix Paeoniae Rubra, Semen Persicaes.Experimental results demonstrate that the cassia twig tuckahoe dispersible tablet has the merit of blood circulation promoting and blood stasis dispelling, tissue regeneration promoting, QI and blood regulating, be the disappear good agent of abdominal mass of blood stasis dispelling.Curing mainly the married woman place has abdominal mass piece, the stasis of blood to stay uterus, pregnant frequent fetal movement, persistent vaginal bloody discharge person.Also can be used for diseases such as hysteromyoma, endometriosis, postpartum lochiorrhea, chronic pelvic inflammatory enclosed mass, dysmenorrhea, ovary be swollen.In addition, treatment appendicitis, adhesive incomplete intestinal obstruction, pleural adhesion and ectopic pregnancy are all obtained satisfactory effect.
In addition, because of the cassia twig tuckahoe dispersible tablet because selected disintegrating agent has water insoluble (or not exclusively water-soluble) and bibulous characteristics, hydrone penetrates among the tablet by capillarity or expansion, suction back powder expands and does not dissolve, do not form sol solution, the further disintegrate that is unlikely to hinder the continuation infiltration of hydrone and influences tablet, so characteristics that the speed that has this dispersible tablet collapses, fully disintegrate in general 3 minutes in 19～21 ℃ of water has improved the trap of medicine greatly; The dispersible tablet disintegration rate is fast, and put into water and can be dispersed into uniform suspension, taking convenience, and absorb comparatively fast, fully, can improve bioavailability of medicament.
Moreover, cassia twig tuckahoe dispersible tablet preparation technology of the present invention is simple, stability is strong, and dispersible tablet is put into water and can be dissolved rapidly and form uniform mixture solution, the selection of adjuvant is not required select effervescent and water soluble adjuvant, working condition does not have specific (special) requirements, disperses the back oral or swallow in the water.
Description of drawings
Fig. 1 is the process flow diagram that the present invention prepares the cassia twig tuckahoe dispersible tablet.
The specific embodiment
Cassia twig tuckahoe dispersible tablet of the present invention mainly is prepared from by adjuvants such as Chinese medicine of the five flavours such as Ramulus Cinnamomi, Poria, Cortex Moutan, Radix Paeoniae Rubra, Semen Persicae and crospolyvinylpyrrolidone, micropowder silica gel, magnesium stearate, microcrystalline Cellulose, carboxymethyl starch-sodium, wherein:
Ramulus Cinnamomi: be monarch drug in the side, warm in nature for the dry twig of canella Cortex Cinnamomi Cinnamomumcassiapresl, acrid in the mouth, sweet, GUIXIN, lung, spleen warp have the diaphoresis expelling pathogenic factors from muscles, effects such as warming the meridian for promoting the flow of YANG QI.Its composition is mainly volatile oil, Main Ingredients and Appearance is cinnamic aldehyde (cinnam idehyde) in the oil, secondly also contain a series of volatile ingredients such as camphene, benzaldehyde, B-elemene, cinnamic alcohol acetas, coumarin, water solublity mainly is cinnamic acid, protocatechuic acid and other glucoside etc., for various effective ingredient all can be extracted fully, water is carried after the first alcohol extraction of process using of the present invention.
Cortex Moutan: this product is the root bark of cohosh Paeonia suffruticosa Paeonia suffruticosa, it is again Cortex Moutan, cold nature, acrid in the mouth, hardship, GUIXIN, liver, kidney channel, function heat clearing away, removing heat from blood, invigorate blood circulation, repercussive, liposoluble constituent mainly contains paeonol and other volatile oil, water soluble ingredient mainly is glycoside compositions such as peoniflorin, benzoylpaeoniflorin.So propose processing with water after the Ramulus Cinnamomi first alcohol extraction simultaneously.
Poria: Poria is a monarch drug with Ramulus Cinnamomi in we altogether, this product is the dry sclerotia of Polyporaceae plant Poria Poria cocos (Schiw) Wolf, property is put down, sweet in the mouth, light, GUIXIN, spleen, kidney channel, energy promoting diuresis to eliminate damp pathogen, spleen invigorating invigorating middle warmer, tranquilizing by nourishing the heart, the main B-pachyman and three that contains pastes compounds, compositions such as Poria alcohol, piece Siberian cocklebur alcohol.
Radix Paeoniae Rubra: be the dry root of cohosh Radix Paeoniae Paeonia lactiflora Pall, cold nature, liver, spleen channel are returned in little acid of distinguishing the flavor of.Energy clearing away heat and cooling blood, eliminating stasis to stop pain mainly contain peoniflorin, the pseudo-ester glycosides of Radix Paeoniae in this product, Hydroxy peoniflorin and three obedient compounds are water soluble ingredient.
Semen Persicae: rosaceous plant peach Prunus persical Batsch or by the seed of the drying and ripening of peach Prunusdavidiana (Carr.) Franch, property is put down, bitter in the mouth, glycosides, GUIXIN, liver, large intestine channel, the function blood circulation promoting and blood stasis dispelling, loosening bowel to relieve constipation mainly contains amygdaloside, emulsin, vitamin B, and waved wet goods on a small quantity, get the effect of its blood circulation promoting and blood stasis dispelling among the we.
Poria, Radix Paeoniae Rubra, Semen Persicae three flavor Chinese medicines according to the dissolution properties and the analysis of physical and chemical property of its effective ingredient, all should be used water extraction, so adopt water extraction process.
The hot glycosides of Ramulus Cinnamomi in the side and temperature, promoting blood circulation; The sweet light eliminating dampness by diuresis of Poria, it is capable to ooze diarrhea, revisal gas, two flavors are monarch drug altogether.The stasis of blood is then heat-transformation for a long time, and Cortex Moutan, Radix Paeoniae removing pathogenic heat from blood and dissipating blood stasis are then arranged, and is stagnant in the Radix Paeoniae promoting the circulation of blood, Cortex Moutan repercussive blood, blood stasis dispelling eliminating mass; Semen Persicae performance removing blood stasis knot, eliminating blood stasis to promote regeneration of blood is the minister assistant altogether.Close the side of forming, cold temperature is also executed, and heresy is just taken into account, and is blood stasis dispelling, the flat agent of the scar that disappears.Full side's function warming the meridian and promoting blood circulation, blood circulation promoting and blood stasis dispelling, the slow scar piece that disappears are used for that lower abdomen has stasis of blood piece due to women's blood stasis, and menorrhagia or persistent vaginal bloody discharge, dark, the many clot of color purple, lower abdomen dull pain or lower abdomen pain with tenderness, dimly red tongue have ecchymosis, hesitant pulse or red.
Among the present invention, be example to suppress 1000 dispersants, its prescription is:
Ramulus Cinnamomi 100-500 gram Poria 100-500 gram Cortex Moutan 100-500 gram
Radix Paeoniae Rubra 100-500 gram Semen Persicae 100-500 gram beta-schardinger dextrin-10-50 gram
Crospolyvinylpyrrolidone 20-150 gram micropowder silica gel 1-10 gram
Magnesium stearate 0.5-10 gram microcrystalline Cellulose 50-300 gram
Carboxymethyl starch-sodium 50-300 gram.
Present embodiment is an example to suppress 1000 dispersants, and its prescription is:
Ramulus Cinnamomi 100-500 gram Poria 100-500 gram Cortex Moutan 100-500 gram
Radix Paeoniae Rubra 100-500 gram Semen Persicae 100-500 gram beta-schardinger dextrin-10-50 gram.
Crospolyvinylpyrrolidone 20-150 gram micropowder silica gel 1-10 gram
Magnesium stearate 0.5-10 gram microcrystalline Cellulose 50-300 gram
Carboxymethyl starch-sodium 50-300 gram.
Its preparation technology please refer to Fig. 1, mainly may further comprise the steps:
(1) Ramulus Cinnamomi, Cortex Moutan mixing are extracted to handle and are made medicinal liquid and medicinal residues;
(2) the gained medicinal liquid is concentrated, and in concentrated solution, add beta-schardinger dextrin-, make fine powder through mixing, drying, pulverizing;
(3) Poria, Radix Paeoniae Rubra, the medicinal residues of Semen Persicae in step (1) are decocted in water, separate medicinal residues and make decocting liquid;
(4) the decocting liquid in the step (3) is concentrated, dry, pulverizing forms fine powder;
(5) fine powder of step (2) and step (4) mixes and adds adjuvant, through granulation, and is pressed into dispersible tablet.
Above-mentioned steps (1) is Ramulus Cinnamomi, a Cortex Moutan of at first selecting formula ratio for use, and it is added with respect to 90% alcohol reflux of Ramulus Cinnamomi, 8 times of amounts of Cortex Moutan gross weight 2 times, and each 1～2 hour, this real embodiment was 1.5 hours.Filter after the extraction, medicinal residues device are in addition preserved, and merging filtrate reclaims ethanol, thereby makes medicinal liquid and medicinal residues.
1.00 gram/cubic centimetres when in the step (2) medicinal liquid being concentrated into relative density and being 50～60 ℃, left standstill 24 hours, get its supernatant, adding is with respect to the beta-schardinger dextrin-of medicinal liquid 8% weight, and under 50～60 ℃, be incubated 20～40 minutes, be incubated 30 minutes down in 50 ℃ in the present embodiment, add 50～60 ℃ water again with respect to 2 times of weight of medicinal liquid, select 50 ℃ water in the present embodiment for use, stirred 20～40 minutes, stirred 30 minutes in the present embodiment, put 10 ℃ of following cold preservations of temperature 60～80 hours, cold preservation is 72 hours in the present embodiment, with the filter cake cold drying, and is ground into fine powder after the filtration.
In the step (3), the Semen Persicae of formula ratio is smashed to pieces, decoct with water 2 times with Poria, Radix Paeoniae Rubra and the aforementioned Ramulus Cinnamomi of formula ratio, the medicinal residues mixture after the Cortex Moutan alcohol extraction, add for the first time water with respect to 10 times of amounts of described mixture weight, add for the second time 8 times of water gagings, the each decoction 1～2 hour decocted 1.5 hours in the present embodiment, made decocting liquid after the filtration.
The clear paste of 1.12～1.15 gram/cubic centimetres when in the step (4) decocting liquid being concentrated into relative density and being 50～60 ℃, drying under reduced pressure forms dried cream, and dried cream powder is broken into fine powder.
In the step (5), after the fine powder mixing with step (2) and step (4), add crospolyvinylpyrrolidone 20-150 gram, carboxymethyl starch-sodium 50-300 gram and microcrystalline cellulose 50-300 gram, with ethanol is that binding agent prepares soft material, add crospolyvinylpyrrolidone 10-100 gram, carboxymethyl starch-sodium 5-50 gram, micropowder silica gel 1-10 gram and magnesium stearate 0.5-10 gram after the granulation again, mixing is pressed into 1000.
By the cassia twig tuckahoe dispersible tablet of aforementioned prescription and prepared cure mainly that function is invigorated blood circulation, blood stasis dispelling, abdominal mass disappears.Being used for the married woman place has the abdominal mass piece, or the blood stasis amenorrhea, menalgia, prolonged lochia.Its safety, effectively, dosage is little and curative effect is strong.It has, and speed collapses, taking convenience, characteristics such as bioavailability of medicament height.And preparation technology is simple, stability is strong, and dispersible tablet is put into water and can be dissolved rapidly and form uniform mixture solution, the selection of adjuvant is not required select effervescent and water soluble adjuvant, and working condition does not have specific (special) requirements, disperses the back oral or swallow in the water.
Below be the pharmacology and the toxicological test of cassia twig tuckahoe dispersible tablet of the present invention:
Example one: the effect of the slow addiction knot that disappears.
With mice group (administration group and matched group) and gastric infusion, once a day, continuous 6 days, observe microcirculation of mouse auricle artery and vein caliber before and after the administration respectively and be equipped with mobility and calculate difference before and after it, the result shows: Ramulus Cinnamomi Poria pill group and matched group relatively have significant difference, and significantly microcirculation improvement state of Ramulus Cinnamomi Poria pill is described.Blood stasis be one with the associated pathological process of microcirculation disturbance, the blood stasis patient has the microcirculation function disorder more, Ramulus Cinnamomi Poria pill may be expanded the blood capillary caliber, promotes little blood flow, and microcirculation improvement state and reach the effect of blood circulation promoting and blood stasis dispelling.
Example two: to Immune Effects.
With mice group (administration group and matched group) and gastric infusion 7 days, 12 hours every mouse peritoneal injection chicken erythrocyte suspensions are 1 milliliter after irritating stomach in the 7th day, take off neck after 10 hours and put to death mice, with 2.5 milliliters of flushings of Chinese Grignard solution abdominal cavity, get peritoneal fluid a little, drip on microscope slide, incubated 30 minutes in 37 ℃ of casees, take out the not attached parietal cell of flush away, drying, 100 times of mirrors are observed down and are calculated the huge percentage phagocytic index when of biting.The result shows: administration group and matched group relatively have significant difference, show that cassia twig tuckahoe can significantly strengthen the huge phagocytic function of biting, enhancing body non-specific immunity.
Example three: to the effect of chronic granulation tissue hyperplasia.
With mice group (administration group and matched group), be made into the roughly the same cotton balls of shape with absorbent cotton, be imbedded at oxter, mice both sides after the sterilization respectively, operation back gastric infusion next day continuous 7 days, is put to death, take out granulation tissue, drying, scales/electronic balance weighing calculates heeling-in front and back cotton balls weight difference.The result shows: administration group and matched group have been compared significant difference, illustrate that Ramulus Cinnamomi Poria pill has inhibitory action to chronic granulation tissue hyperplasia.
Example four: to the influence of estradiol, Progesterone, prolactin antagonist.
Get 100 of female sd inbred rats and give rats by intraperitoneal injection estradiol benzoate and Progesterone, make high estradiol, Progesterone rat model.Rat is divided into 5 groups at random: blank group, model group, tamoxifen matched group, cassia twig tuckahoe dispersible tablet 200mg/kg group, and cassia twig tuckahoe dispersible tablet 400mg/kg group, 20 every group.Blank group and model group are given the equal-volume distilled water, and all the other groups are given tamoxifen 3mg/kg, cassia twig tuckahoe dispersible tablet suspension 200mg/kg and 400mg/kg respectively.Irritate stomach every day, totally 30 days.Measure the content of respectively organizing estradiol, Progesterone, prolactin antagonist in the experimental rat model blood plasma with radioimmunoassay.The result: cassia twig tuckahoe dispersible tablet 200mg/kg and 400mg/kg group can obviously reduce high female, progestogen rat model plasma estradiol and Progesterone, these two groups of estradiol are respectively (127 ± 52) ng/L and (153 ± 49) ng/L, Progesterone is respectively (12 ± 8) μ g/L and (13 ± 7) μ g/L, compare with model group estradiol (271 ± 103) ng/L and Progesterone (21 ± 15) μ g/L, the equal significance of difference, P＜0.05, but little to the influence of blood plasma prolactin antagonist.The result shows: the cassia twig tuckahoe dispersible tablet can significantly reduce female, the progestogen of experimental height of unusual rising, the blood concentration of rat model plasma estradiol and Progesterone.
Example five: toxicology.
Mice is divided into three groups: administration group (the cassia twig tuckahoe dispersible tablet is made suspension), blank group (normal saline), positive controls (cyclophosphamide), adopt disposable gastric infusion, and administration was put to death animal after 24 hours.Get its bone marrow and make smear, methanol is fixed 10 minutes, with the erythrocytic micronucleus number of Giemsa dyeing 1000 bone marrow polychromatophilia of (PH=6.8) every mice microscopy, micronucleus go out the reason rate with ‰ expression, and it is red and just incarnadining the ratio of cell, processing by statistics to calculate polychromatophilia, determine the P value, judged result.In the experiment dosage of used cassia twig tuckahoe be respectively 123,61.5,30.75g/kg, the LDso＞246g/kg of cassia twig tuckahoe, selected maximal dose is 1/2Ldso in the experiment.Show that from micronucleus test the various dose group of cassia twig tuckahoe dispersible tablet does not have significance increases the erythrocytic micronuclear rates of mouse bone marrow cells polychromatophilia, illustrate that this medicine does not have the hereditary material existence of damage bone marrow cells in mice in the used dosage range of this experiment.
Claims (7)
1, a kind of cassia twig tuckahoe dispersible tablet, the prescription that is pressed into 1000 is composed of the following components:
Ramulus Cinnamomi 100-500 gram Poria 100-500 gram Cortex Moutan 100-500 gram
Radix Paeoniae Rubra 100-500 gram Semen Persicae 100-500 gram beta-schardinger dextrin-10-50 gram.
Crospolyvinylpyrrolidone 20-150 gram micropowder silica gel 1-10 gram
Magnesium stearate 0.5-10 gram microcrystalline Cellulose 50-300 gram
Carboxymethyl starch-sodium 50-300 gram.
2, cassia twig tuckahoe dispersible tablet as claimed in claim 1 is characterized in that: with medical material and the adjuvant of suppressing 1000 dispersible tablets be:
Ramulus Cinnamomi 360 gram Poria 360 gram Cortex Moutans 360 grams
Radix Paeoniae Rubra 360 gram Semen Persicaes 360 gram beta-schardinger dextrin-s 36 grams
Crospolyvinylpyrrolidone 75 gram micropowder silica gels 5 grams
Magnesium stearate 2.5 gram microcrystalline Cellulose 175 grams
Carboxymethyl starch-sodium 90 grams.
3, a kind of manufacture method of cassia twig tuckahoe dispersible tablet is characterized in that: carry out according to the following steps:
(1) takes by weighing each 100-500 gram of Ramulus Cinnamomi, Cortex Moutan and mix, add again, each 1～2 hour, make medicinal liquid and medicinal residues after the filtration with respect to 90% alcohol reflux of Ramulus Cinnamomi, 8 times of amounts of Cortex Moutan gross weight at least 2 times;
(2) the gained medicinal liquid is concentrated, leave standstill the supernatant of getting concentrated solution after 24 hours, and in this supernatant, add 10～50 the gram beta-schardinger dextrin-s, and under 50～60 ℃, be incubated 20～40 minutes, add 50～60 ℃ water again, stirred 20～40 minutes, place 10 ℃ of following cold preservations of temperature 60～80 hours with respect to 2 times of weight of medicinal liquid, with the filter cake cold drying, open pulverizing and make fine powder after the filtration;
(3) medicinal residues of each 100-500 gram of Poria, Radix Paeoniae Rubra, Semen Persicae with step (1) in are decocted separation medicinal residues and make decocting liquid in water;
(4) the decocting liquid in the step (3) is concentrated, dry, pulverizing forms fine powder;
(5) fine powder of step (2) and step (4) mixes and adds adjuvant, through granulation, and is pressed into dispersible tablet.
4, the manufacture method of cassia twig tuckahoe dispersible tablet as claimed in claim 3 is characterized in that: with medical material and the adjuvant of suppressing 1000 dispersible tablets be:
Ramulus Cinnamomi 360 gram Poria 360 gram Cortex Moutans 360 grams
Radix Paeoniae Rubra 360 gram Semen Persicaes 360 gram beta-schardinger dextrin-s 36 grams
Crospolyvinylpyrrolidone 75 gram micropowder silica gels 5 grams
Magnesium stearate 2.5 gram microcrystalline Cellulose 175 grams
Carboxymethyl starch-sodium 90 grams.
5, the manufacture method of cassia twig tuckahoe dispersible tablet as claimed in claim 3 is characterized in that: it is 1.00 gram/cubic centimetres when medicinal liquid is concentrated into relative density and is 50～60 ℃ that described step (2) herb liquid concentrates.
6, the manufacture method of cassia twig tuckahoe dispersible tablet as claimed in claim 3, it is characterized in that: the decocting liquid in the described step (3) is that Semen Persicae is smashed to pieces, decoct with water at least 2 times with the medicinal residues mixture after Poria, Radix Paeoniae Rubra and Ramulus Cinnamomi, the Cortex Moutan alcohol extraction, add for the first time water with respect to 10 times of amounts of described mixture weight, add for the second time 8 times of water gagings, the each decoction 1～2 hour makes decocting liquid after the filtration.
7, the manufacture method of cassia twig tuckahoe dispersible tablet as claimed in claim 3 is characterized in that: in the described step (4) decocting liquid being concentrated is the clear paste of 1.12～1.15 gram/cubic centimetres when concentrated solution is concentrated into relative density and is 50～60 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100514849A CN100355416C (en) | 2004-09-10 | 2004-09-10 | Cassia twig and poria cocos disperse tablet and its producing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100514849A CN100355416C (en) | 2004-09-10 | 2004-09-10 | Cassia twig and poria cocos disperse tablet and its producing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1615978A CN1615978A (en) | 2005-05-18 |
| CN100355416C true CN100355416C (en) | 2007-12-19 |
Family
ID=34764017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100514849A Expired - Fee Related CN100355416C (en) | 2004-09-10 | 2004-09-10 | Cassia twig and poria cocos disperse tablet and its producing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100355416C (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101491606B (en) * | 2008-12-31 | 2011-11-30 | 四川禾邦阳光制药股份有限公司 | Micro-pills of cassia twig and Tuckahoe and preparation method thereof |
| CN104306541A (en) * | 2014-11-26 | 2015-01-28 | 黑龙江省智诚医药科技有限公司 | Traditional Chinese medicine dispersible tablet capable of nourishing blood and tranquilization and preparation method thereof |
| CN104523898A (en) * | 2014-12-15 | 2015-04-22 | 北京汉典制药有限公司 | Preparation method of traditional Chinese medicine extract, traditional Chinese medicine extract prepared by preparation method and use of traditional Chinese medicine extract |
| CN104800319A (en) * | 2015-04-14 | 2015-07-29 | 淄博夸克医药技术有限公司 | Traditional Chinese medicine for treating uterus fibroids |
| CN110496197A (en) * | 2019-08-28 | 2019-11-26 | 河南世豪医药科技有限公司 | A kind of drug and preparation method thereof for treating fibroid |
| CN111759994A (en) * | 2020-08-25 | 2020-10-13 | 龚汝儒 | Boehuo pill for radically treating hyperplasia of mammary glands, cyst, nodule and myoma and its preparing method |
| CN113750211A (en) * | 2021-09-02 | 2021-12-07 | 徐州康正中医药科技有限公司 | Medicine and food homologous traditional Chinese medicine formula for treating lochiorrhea in puerperium women |
| WO2023128710A1 (en) * | 2021-12-30 | 2023-07-06 | 주식회사 큐라클 | Tablet containing mixed extract of cinnamomi ramulus and moutan radicis cortex as active ingredient and composition designed to administer specific dosage thereof for treatment |
-
2004
- 2004-09-10 CN CNB2004100514849A patent/CN100355416C/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 化学工业出版社 国家药典委员会编.中华人民共和国药典，第1期 2000 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1615978A (en) | 2005-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103990081B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating infant jaundice | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN102784363B (en) | Traditional Chinese medicine composition for treating pancreatic cancer and preparation method thereof | |
| CN103007234A (en) | Traditional Chinese medicine preparation for treating dysmenorrheal caused by endometriosis and preparation method of preparation | |
| CN105749179A (en) | Traditional Chinese medicine composition for treating metabolic syndrome | |
| CN105920514A (en) | Traditional Chinese medicinal composition for treating metabolic syndrome | |
| CN104958607A (en) | Traditional Chinese medicine composition for treating burning mouth syndromes of climacteric women and preparation method thereof | |
| CN100355416C (en) | Cassia twig and poria cocos disperse tablet and its producing method | |
| CN101095923B (en) | Chinese traditional medicine for treating ectopic pregnancy | |
| CN101953936A (en) | Traditional Chinese medicine preparation for treating immune thrombocytopenia and preparation method thereof | |
| CN101537159B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN103705860B (en) | A kind of Chinese medicine composition for the treatment of infant jaundice and preparation method thereof | |
| CN104906403A (en) | Folium apocyni veneti health oral liquid capable of decreasing blood pressure and lipid and preparation method thereof | |
| CN101485867A (en) | Chinese medicinal composition for treating varix and preparation method thereof | |
| CN103157062A (en) | Medicine composition curing gynaecological mass diseases such as fibroids and preparation method and application thereof | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN103735792B (en) | A kind of medicine for the treatment of menoxenia and preparation method thereof | |
| CN103212030B (en) | Traditional Chinese medicine for treating liver depression type hyperplasia of mammary glands and preparation method thereof | |
| CN103041233A (en) | Pharmaceutical composition for treating infantile diarrhea and preparation method thereof | |
| CN102293985A (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN102847060A (en) | Traditional Chinese medicine composition for treating uterine myoma and preparation method thereof | |
| CN100594923C (en) | Oral administered medicinal composition and its preparation and usage | |
| CN101439150A (en) | Chinese medicinal composition for treating intestinal inflammation | |
| CN105853796A (en) | Medicine composition for treating habitual abortion | |
| CN106511881B (en) | A Chinese medicinal composition for invigorating kidney and preventing miscarriage, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Shenzhen Guoyuan Pharmaceutical Co.,Ltd. Assignor: Zhang Kai Contract fulfillment period: 2009.11.10 to 2024.9.9 Contract record no.: 2009440001839 Denomination of invention: Cassia twig and poria cocos disperse tablet and its producing method Granted publication date: 20071219 License type: Exclusive license Record date: 2009.12.1 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.11.10 TO 2024.9.9; CHANGE OF CONTRACT Name of requester: SHENZHEN GUOYUAN PHARMACEUTICAL CO., LTD. Effective date: 20091201 |
|
| EM01 | Change of recordation of patent licensing contract |
Change date: 20130829 Contract record no.: 2009440001839 Assignee after: Shenzhen national source of Chinese Medicine Co., Ltd. Assignee before: Shenzhen Guoyuan Pharmaceutical Co.,Ltd. |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CI01 | Correction of invention patent gazette |
Correction item: Assignee of record for patent exploitation license contracts Correct: Shenzhen Guoyuan Sinopharm Co., Ltd. False: Shenzhen national source of Chinese Medicine Co., Ltd. Number: 44 Volume: 29 |
|
| ERR | Gazette correction | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071219 Termination date: 20180910 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |